Scientific Program

(as of May 2023)

Wednesday, May 31, 2023

17h00 – 18h00

General Assembly E-ISFA
(by invitation only)

Thursday, June 1, 2023

08h30 – 08h55

Opening Ceremony
Bernd Hohenstein, ISFA President (DE), Wolfgang Ramlow, E-ISFA President (DE)

Congress Opening by
Bernd Hohenstein, ISFA President (DE)
Wolfgang Ramlow, E-ISFA President (DE)
Ulrich Julius, Honorary Congress President E-ISFA (DE)
Horst Klinkmann, Honorary Congress President ISFA (DE)


09h00 – 10h20

Apheresis around the world I:
Country specific aspects

Shamanna Iyengar (Bangalore, IN)
Olivier Moranne (Nimes, FR)

Kurt Derfler (Institute ATHOS, Vienna, AT)
Organization and national activities of therapeutic apheresis in Austria

Ken Yamaji (Juntendo University, Tokyo, JP)
Organization and national activities of therapeutic apheresis in Japan

Amber Sanchez (University of California San Diego, US)
Organization and national activities of therapeutic apheresis in the USA

Selected from abstracts:
Nosakhare G. Bazuaye
et al. (Igbinedion University Teaching Hospital, Benin, Nigeria)
Apheresis activities in a low resource country Nigeria: a five years report of a single center

Lipid disorders and CVD I:
Lipid disorders – it all starts with the measurement

Patrick Moriarty (Kansas City, US)
Jeffrey Kroon (Amsterdam, NL)

Patrick Moriarty (University of Kansas Medical Center, Kansas City, US)
Lipoprotein-apheresis and its effect on HDL functionality

Johanna Schachtl-Riess (Medical University of Innsbruck, AT)
Lipoprotein(a) – from genetics to phenotype

Jeffrey Kroon (University of Amsterdam, NL)
Evidence for a strong pro-inflammatory potential of lipoprotein(a)

Winfried März (SYNLAB Akademie, DE)
Dyslipidemia – it all starts with a correct measurement

10h20 – 10h45

Coffee Break, Exhibition & Poster Viewing

10h45 – 12h05

Apheresis around the world II:
South East Asian perspectives

Sasitorn Siritho (Bangkok, TH)
Wolfgang Ramlow (Rostock, DE)

Sasitorn Siritho (Bumrungrad International Hospital, TH)
Systematic review of TPE practices in central neuroimmunological disorders: evolving concepts in South East Asia

Lu Fiong Hiew (Kuala Lumpur Hospital, MY)
Uniting the world through TPE: SEATPEC challenges & potential future collaborations

Nghia Hoang (Military Hospital, Ho Chi Minh, VN)
TPE and its challenges in Vietnam

Dhayalen Krishnan (Kuala Lumpur General Hospital, MY)
Introduction to SEATPEC, best practices and TPE guidelines in South East Asia

Registries as research tools in apheresis

Ulrich Julius (Dresden, DE)
Volker Schettler (Goettingen, DE)

Christian Schumann (MVZ Kempten, DE)
CACOV – an apheresis registry for severely ill acute COVID patients

Bernd Hohenstein (Nephrologisches Zentrum Villingen-Schwenningen, DE)
The German Long-Covid Apheresis Register – design and first experiences

Wanja Bernhardt (Centre for Hypertension, Kidney and Metabolic diseases, Hanover, DE)
The German Lipoprotein Apheresis Register – a specific analysis of Lp(a) apheresis patients

Selected from abstracts:
Phandee Watanaboonyongcharoen et al. (Chulalongkorn University, Bangkok, TH)
A multicenter study of safety and incidence of adverse reactions associated with therapeutic apheresis in Thai patients

Apherese-Weiterbildung in deutscher Sprache:
Teil 1

Jens Ringel (Potsdam, DE)

Uwe Wallstab (Wernigerode, DE)
Apherese ist nicht gleich Apherese

Reinhard Klingel (Köln, DE)
Apherese – mehr als nur Lipidreduktion


12h05 – 12h30

Coffee Break, Exhibition & Poster Viewing

12h30 – 13h45

13h45 – 14h00


14h00 – 15h15

Apheresis around the world III:
Current updates & issues (from the American Society for Apheresis – ASFA)

Bernd Hohenstein (Villingen-Schwenningen, DE)
Joseph (Yossi) Schwartz (Tampa, US)

Joseph (Yossi) Schwartz (Moffit Cancer Center, Florida, US)
Growing variations in collections for further manufacturing

Betty Doggett (Carter BloodCare, Laird Hill, US)
Vascular access – issues & resolutions

Nicole Aqui (Perelman School of Medicine, University of Pennsylvania, US)
ASFA Guidelines for Therapeutic Apheresis – 2023

Autoimmune diseases I
Neuroimmune diseases and immunomodulation

Dhayalen Krishnan (Kuala Lumpur, MY)
Reinhard Klingel (Cologne, DE)

Wolfgang Köhler (Leipzig University, DE)
The role of apheresis therapy in MS and NMOSD

Olivier Moranne (CHU Caremeau Nimes, University Montpellier, FR)
Immunomodulatory effect associated with therapeutic plasmapheresis

Selected from abstracts:
Miriam Lanska et al. (University Hospital and Faculty of Medicine, Hradec Kralove, CZ)
Efficacy and safety of long-term immunoadsorption therapy in patients with myasthenia gravis

Selected from abstracts:
Virginia Athanasiadou et al. (National and Kapodistrial University of Athens, GR)
Therapeutic Plasmapheresis: A safe and effective periodic treatment for chronic inflammatory demyelinating polyneuropathy

Apherese-Weiterbildung in deutscher Sprache:
Teil 2

(14h00 – 15h30)

Jens Ringel (Potsdam, DE)
Ultima ratio bei Lipoproteinstörungen

Jens Ringel (Potsdam, DE)
Apherese, eine erfolgreiche Geschichte

Jörg Müller (Dresden, DE)
Heparin oder Citrat zur Antikoagulation

15h15 – 15h45

Coffee Break & Poster Viewing

15h45 – 17h30

Apheresis around the world IV
Apheresis therapy in Japan – JSFA Workshop

Ken Yamaji (Tokyo, JP)
Wolfgang Ramlow (Rostock, DE)

Ken Yamaj (Juntendo University, Tokyo, JP)
Updated Topics in PE, DFPP and plasma adsorption using the membrane separation

Shuzo Kobayashi (Shonan Kamakura General Hospital, Kanagawa, JP)
A novel LDL/fibrinogen apheresis ‘Rheocarna’ for patients with chronic limb-threatening ischemia

Tomoki Tanaka (Shiga University, Shiga, JP)
The development history of Toraymyxin and the update of clinical data of PMX-DHP

Makoto Naganuma (Kansai Medical University, Osaka, JP)
Developments and future perspective of apheresis therapy for inflammatory bowel disease

Apheresis in critical care medicine

Wladimir Szpirt (Copenhagen, DK)
Jan Kielstein (Braunschweig, DE)

Jan Stange (University Medical Center Rostock, DE)
Recent developments in the field of extracorporeal albumin detoxification (ECAD) for liver support

Gerd Klinkmann (University Medical Center Rostock, Department of Anesthesiology and Intensive Care Medicine, DE)
Extracorporeal immune cell therapy in sepsis

Steffen Mitzner (University Medical Center Rostock, DE)
Cytokine adsorption in sepsis and septic shock – still under debate

Amber Sanchez (University of California San Diego, US)
How to combine multiple extracorporeal systems in critical care

Sascha David (Zurich University Hospital, CH)
TPE in septic shock: to remove and replace

Apherese-Weiterbildung in deutscher Sprache:
Teil 3

(16h00 – 17h45)

Anja Ramlow (Potsdam, DE)
Pflegerische Aspekte in der Apheresebehandlung von
Long/Post-Covid Patienten

Volker Witt (Wien, AT)
Pflegerische Aspekte in der Apheresebehandlung von Kindern

Jens Ringel (Potsdam, DE)
Vorstellung der E-ISFA

Jens Ringel (Potsdam, DE)

17h30 – 19h30

Welcome Reception & Poster Session

Friday, June 2, 2023

08h30 – 09h50

Apheresis around the world V:
Country specific aspects

Amber Sanchez (San Diego, US)
Kurt Derfler (Vienna, AT)

Shamanna Iyengar (Manipal Academy of Higher Education, IN)
On the way to establish a lipid apheresis program in India by Lipid Association of India (LAI)

Ahmad AlSaraf (Sabah AlAhmad Cardiac Center, KW)
LDL apheresis in homozygous familial hypercholesterolemia in Kuwait

Luigi Vernaglione (Perrino Hospital, Brindisi, IT)
Cross sectional analysis of apheretical therapies in Italy

Olivier Moranne (CHU Caremeau Nimes, University Montpellier, FR)
Organization and national activities of therapeutic apheresis in France

Guest workshop:
Association of German Dialysis Centers (DN e. V.)

Georg Schlieper (Hanover, DE)
Wladimir Szpirt (Copenhagen, DK)

Georg Schlieper (Dialysis Centre Hanover, DE)
Is there a role for immunoadsorption in Post Covid?

Volker Schettler (Center of Nephrology, Dialysis and Apheresis, Göttingen, DE)
The German Lipoprotein Apheresis Registry (GLAR) – Summary of the tenth annual report

Jan Kielstein (Braunschweig Hospital, DE)
From sepsis to COVID – apheresis therapy in critical care medicine

09h00 – 12h00

Apherese-Weiterbildung in deutscher Sprache: 

09h50 – 10h20

Coffee Break, Exhibition & Poster Viewing

10h20 – 12h10

Apheresis in COVID-19 and its complications

Julia Weinmann-Menke (Mainz, DE)
Bernd Hohenstein (Villingen-Schwenningen, DE)

Carmen Scheibenbogen (Charité – Universitätsmedizin Berlin, DE)
Long-term consequences of COVID and current therapeutic perspectives

Beate Jäger (Praxis Mühlheim a. d. R., DE)
Long COVID – why apheresis therapy could make the difference

Harald Matthes (Havelhöhe Community Hospital, Berlin, DE)
Is apheresis therapy an option for neuroinflammatory Post-vaccination syndrome?

Ulrich Paul Hinkel (Zentralklinik Bad Berka, DE)
Post-COVID-19 and post COVID-19-vaccination syndrome
Patient reported outcomes after DFPP, summary of 20 cases

Panel discussion – pro and contra

Lipid disorders and CVD II:
Apheresis targeting microcirculation and inflammation

Luigi Vernaglione (Brindisi, IT)
Wanja Bernhardt (Hanover, DE)

Luigi Vernaglione (Perrino Hospital, Brindisi, IT)
Apheresis to improve rheology – indications and results

Dusit Lumlertgul (Faculty of Medicine, Chiang Mai, TH)
Double filtration plasmapheresis (DFPP) to improve microcirculation

Jan Torzewski (Allgäu Hospital Network, Kempten, DE)
CRP – from laboratory parameter to key player of inflammation

Selected from abstracts:
Rosita Bihariesingh
et al. (Academic Hospital Paramaribo Suriname)
First-in-Man: Plasmapheresis with a novel blood separation device in hypertriglyceridemia and acute pancreatitis

Selected from abstracts:
Mohamed Sedky et al. (Kuwait Central Blood Bank)
A fifteen-years analysis of therapeutic apheresis practices in state of Kuwait

Selected from abstracts:
Sergei Pokrovsky
(National Medical Research Centre of Cardiology, Moscow, RU)
The contribution of Russian Scientists to the development of adsorption columns for therapeutic apheresis

12h10 – 12h30

Lunch Break, Exhibition & Poster Viewing

12h30 – 13h45

13h45 – 14h00

Lunch Break, Exhibition & Poster Viewing

14h00 – 15h20

Treatment approaches in COVID and its consequences

Yoshihiro Endo (Otsu, Shiga, JP)
Steffen Mitzner (Rostock, DE)

Wladimir M. Szpirt (Rigshospitalet, Copenhagen, DK)
Plasma exchange utilizing convalescent plasma in severe COVID patients

Sebastian Koball (University Medical Center Rostock, DE)
How to evaluate apheresis efficacy in patients suffering from Long COVID?

Gunnar Bücker (Nephrology group practice, Osnabrück, DE)
First clinical results after HELP apheresis in Long COVID Syndrome

Julia Weinmann-Menke (Universitätsmedizin Mainz, DE)
Removal of circulating antibodies to adenoassociated virus vectors by immunoadsoption

New guidelines and developments:
Technical regulations and developments

Victoria Weber (Krems, AT)
Andre Kaplan (Plainvile, US)

Uwe H. Wallstab (mdXperts GmbH, Cologne, DE)
Relevance of sufficient clinical safety and performance data to maintain CE mark of apheresis devices

Viktoria Weber (Danube University Krems, AT)
Influence of the column surface on therapeutic apheresis – an old issue but new developments are rising

Selected from abstracts:
Andrew Aswani
et al. (Santersus AG, CH)
Safety and performance of the NucleoCapture®Column for selective cfDNA/NETs apheresis in patients with sepsis

Selected from abstracts:
Kensuke Owari
et al. (TAGCyx Biotechnologies, Inc., Tokyo, JP)
Development of next generation apheresis using artificial base DNA Aptamer

Lipid disorders and CVD III:
Workshop German Lipid League

Anja Vogt (Munich, DE)
Volker Schettler (Goettingen, DE)

Oliver Weingärtner (University Hospital Jena, DE)
A nationwide initiative to reach lipid targets

Anja Vogt (Ludwig Maximilians University Hospital, Munich, DE)
Novel lipid lowerting medications – current status and future perspectives

Ulrich Julius (University Hospital Dresden, DE)
Cardiovascular events before and during apheresis treatment – a detailed analysis for vascular regions

13h00 – 15h30

Apherese-Weiterbildung in deutscher Sprache: 


Gruppenarbeit an den verschiedenen Maschinen mit Erfahrungsaustausch unter den Pflegenden zu je 150 min
(unter Beteiligung der Medizinprodukte-Hersteller)

 Jens Ringel (Potsdam, DE) Verabschiedung

15h20 – 15h45

Coffee Break, Exhibition & Poster Viewing

15h45 – 17h30

Lipid disorders and CVD IV:
Treatment modalities in clinial practice

Mariko Harada-Shiba (Osaka, JP)
Tiziana Sampietro (Pisa, IT)

Wanja Bernhardt (Dialysis Centre Hanover, DE)
Long-term experience of Lp(a) apheresis in outpatient care

Tiziana Sampietro (National Research Council Institute of Clinical Physiology, Pisa, IT)
The role of lipoprotein apheresis on hypercholesterolemia and Lp(a) – the Pisa experience

Ulrich Julius (University Hospital Dresden, DE)
Comparison of the plasma lipoprotein apheresis systems MONET and Lipidfiltration from Diamed vs. the whole blood apheresis system DALI in the treatment of patients with cardiovascular disease and severe dyslipidemia

Jannecke Mulder (NL)
Quality of life in Dutch hoFH patients

Mariko Harada-Shiba (National Cerebral and Cardiovascular Center, Osaka, JP)
Development of novel drug for primary chylomicronemia by using antisense

Autoimmune diseases II:
Apheresis in rheumatologic and inflammatory bowel disease

Ken Yamaji (Tokyo, JP)
Harald Matthes (Berlin, DE)

Andreas Kronbichler (Medical University Innsbruck, AT)
Apheresis therapy in autoimmune vasculitides – PEXIVAS is not the end

Yoshihiro Endo
(Shiga University of Medical Science, Otsu, JP)
Novel hemo-adsorbent for ulcerative colitis in Japan

Makoto Naganuma (Keio University School of Medicine, Tokyo, JP)
Recent trends of apheresis treatment for inflammatory bowel disease

Ken Yamaji (Juntendo University, Tokyo, JP)
Is apheresis therapy still an option in rheumatic diseases?

Selected from abstracts:
Natalia Jarzebska
(University Hospital Dresden)
Apheresis treatment leads to increased levels of circulating neutrophil extracellular traps

Apheresis Service and Education 
(in English language)

Betty Doggett (Laird Hill, US)
Rasheed Balogun (Charlottesville, US)

Christopher Dixon et al. (NHS Blood and Transplant, UK)
NHS Blood and Transplant – A Gold Standard Therapeutic Apheresis Service Model

Bridget Audsley et al. (NHS Blood and Transplant, NHS, Barnsley, UK)
Education and traininig in apheresis

Betty Doggett et al. (Carter BloodCare, Laird Hill, US)
Alliances and challenges of a community blood center mobile apheresis program providing care for donors and patients during COVID-19

Luigi Vernaglione et al. (Perrino Hospital, Brindisi, IT)
Effectiveness of therapeutic apheresis (TA): experience and outcomes analysis in an italian center

Rasheed Balogun (University of Virginia, Charlottesville, US)
Vascular access options for therapeutic apheresis

18h45 – 23h00

Congress Dinner

Saturday, June 3, 2023

08h30 – 10h15

Autoimmune diseases III
Apheresis for renal diseases

Andreas Kronbichler (Innsbruck, AT)
Wladimir Szpirt (Copenhagen, DK)

Lionel Rostaing (CHU Grenoble Alpes, Grenoble, FR)
Apheresis and desensitization before kidney transplantation

Benjamin Savenkoff (CHR Metz-Thionville, FR)
The role of apheresis therapy in glomerulopathies

Vladimir Kuklin (Bruggemann) (Ahus University Hospital, Lorenskog, NO)
Influence of therapeutic plasma exchange treatment on early survival of septic patients: a systematic review and meta-analysis

Wladimir Szpirt (Rigshospitalet, Copenhagen, DK)
An evolution in treatment of anti GBM nephritis – plasma exchange or imlifidase?

Selected from abstracts:
Haruna Yoshida et al. (Osaka City General Hospital)
Selective plasma exchange in critical care

Selected from abstracts:
Noemi Elisabeth Ginthör et al. (Medical University of Graz, AT)
Evaluation of iron deficiency and mechanisms of potential iron loss in patients undergoing immunoadsorption

Lipids and CVD V:
Pleiotropic and other expected windfall gains

Dursit Lumlertgul (Chiang Mai, TH)
N. N.

Grit Waitz (BioArtProducts, Rostock, DE)
Cardiometabolic risk assessment – the impact of comorbidities

Mariko Harada-Shiba (National Cerebral and Cardiovascular Center, Osaka, JP)
Lipoprotein apheresis for the treatment of familial hypercholesterolemia in Japan

Takafumi Ito (JP)
Efficacy and safety of LDL apheresis for the treatment of cholesterol crystal embolism

Selected from abstracts:
Lena Jochheim et al. (University Hospital Dresden, DE)
Actual situation at the Dresden Lipoprotein Apheresis Centre in 2023

Selected from abstracts:
Volker Schettler et al. (German Center for Neurodegenerative Diseases (DZNE) Goettingen, DE)
Effective exosomes reduction in hypercholesterinemic patients suffering from cardiovascular diseases by lipoprotein apheresis: exosomes pheresis

Selected from abstracts:
Romy Walther (University Hospital Dresden, DE)
Prognostic value of plasma lipidome for determining the risk of cardiovascular events in patients with lipoprotein apheresis

10h15 – 10h45

Coffee Break, Exhibition & Poster Viewing

10h45 – 12h30

Future perspectives of apheresis therapy
The future perspectives of apheresis

Bernd Hohenstein (Villingen-Schwenningen, DE)
Wolfgang Ramlow (Rostock, DE)

Patrick Moriarty (University of Kansas Medical Center, Kansas City, US)
Future perspectives in apheresis therapy – lipoprotein apheresis

Jan Kielstein (Braunschweig Hospital, DE)
Future perspectives in apheresis therapy – critical care medicine

Lionel Rostaing (CHU Grenoble Alpes, Grenoble, FR)
Future perspectives in apheresis therapy – renal diseases and transplantation

Reinhard Klingel (Apheresis Research Institute, Cologne, DE)
Future perspectives in apheresis therapy – immune-mediated conditions

Pediatric apheresis
Apheresis in children and adolescent patients

Julia Thumfart (Berlin, DE)
Volker Witt (Vienna, AT)

Wolfgang Ries (Diako Hospital Flensburg, DE)
Severe chronic fatigue syndrome (ME/CFS) in children – when is immunoadsorption justified?

Julia Thumfart (Charité – Universitätsmedizin Berlin, DE)
Apheresis therapy for pediatric neurological diseases – a German perspective

Volker Witt (Paediatric Hospital “St. Anna”, Vienna, AT)
ECP in children and young adults – special needs

Selected from abstracts:
Claudia Ootjers et al. (Leiden University Medical Centre)
Erythrocytapheresis prior to allogeneic stem cell transplantation in children with sickle cell disease is a safe and efficient method to lower sickle haemoglobin

Panel discussion:
Particularities in pediatric apheresis

12h30 – 13h00

Closing Ceremony & Awards Presentation



Cookie Consent with Real Cookie Banner